Gufi.Ns

GUFI.NS has a debt-to-equity ratio of 0.56, indicating a moderate reliance on debt financing, and a current ratio of 1.61, suggesting reasonable short-term liquidity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

The company's return on equity (ROE) is 11.59%, and its return on assets (ROA) is 5.96%, both of which are key indicators of profitability and capital efficiency. These figures suggest that GUFI.NS is generating a solid return for its shareholders and effectively utilizing its assets.

GUFI.NS operates in a single business segment, with no disclosed geographic diversification. The company's revenue is entirely attributed to its pharmaceutical operations, and there is no indication of significant geographic concentration or diversification in the provided data.

GUFI.NS has demonstrated a stable financial performance, with a revenue of INR 8.198 billion in the latest reporting period. While the company's capital expenditure is negative, indicating a reduction in capital spending, it is not accompanied by a significant increase in revenue or profitability, suggesting a cautious approach to investment.

The company faces a medium liquidity risk due to its negative net cash position after accounting for total debt. Although the dilution risk is currently low, the company's financial structure and capital allocation decisions could influence this in the future. No recent events or filings have been disclosed that would significantly alter the company's risk profile.

GUFI.NS has not disclosed any recent events, filings, or transcripts that would provide insight into its strategic direction or operational performance. The absence of such information limits the ability to assess the company's response to market conditions or regulatory changes.